HYBRID EVENT: You can participate in person at Baltimore, MD, USA or Virtually from your home or work.

2nd Edition of International Conference on Gastroenterology

October 21-23, 2024, Baltimore, Maryland, USA

October 21 -23, 2024 | Baltimore, MD, USA

Policies and approval of GI drugs

Policies and approval of GI drugs

Gastrointestinal (GI) drugs are medications used to treat conditions related to the digestive system. These drugs work to reduce inflammation, control acid production, and reduce symptoms such as abdominal pain, cramping, and diarrhea. The approval and regulation of GI drugs is a complex process that involves multiple government agencies. In the United States, the Food and Drug Administration (FDA) is responsible for evaluating new drugs for safety and efficacy before they are approved for use. After the FDA reviews a drug and finds it to be safe and effective for its intended use, the agency will issue an approval for its marketing. This approval includes a Drug Facts Label which contains important information about the drug including its side effects and warnings. In addition to the FDA, the Centers for Medicare and Medicaid Services (CMS) also has an important role in the approval process for GI drugs. CMS evaluates the cost effectiveness of drugs that are approved by the FDA. This means that the agency will consider the drug’s cost versus its benefit when determining whether to approve its use. CMS may also establish reimbursement policies that affect the cost of the drug and its availability to patients. In order to ensure that GI drugs are used safely and appropriately, the FDA also has regulations in place that govern the manufacturing, labeling, advertising, and distribution of these drugs. The agency also inspects drug manufacturing facilities to make sure that they are in compliance with these regulations. Finally, the FDA also works with healthcare providers to ensure that GI drugs are prescribed and used appropriately. The agency provides information to healthcare professionals about the safe and effective use of these medications and monitors the use of these drugs to ensure that they are being used properly. By regulating the approval and use of GI drugs, the FDA and CMS help ensure that these medications are safe and effective for their intended use. This helps to ensure that patients receive the best possible care when it comes to treating their gastrointestinal conditions.

Committee Members
Speaker at Gastroenterology Conferences - Philip M Hemken

Philip M Hemken

Abbott Diagnostics Division R&D, United States
Speaker at Gastroenterology Conferences - John Andrew Sutton

John Andrew Sutton

Gastria Ltd, United Kingdom
Speaker at Gastroenterology Conferences - Orestis Ioannidis

Orestis Ioannidis

Aristotle University of Thessaloniki, Greece
Gastro 2024 Speakers
Speaker at GI Conferences - Perry Hookman

Perry Hookman

Light of the World Free Clinic, United States
Speaker at Gastroenterology Conferences - Brandon Lucke Wold

Brandon Lucke Wold

University of Florida, United States
Speaker at GI Conference - Bipneet Singh

Bipneet Singh

Henry Ford Jackson, United States
Speaker at Gastroenterology Conference - Marjorie M. Rooney

Marjorie M. Rooney

Oklahoma State University Center for Health Sciences, United States

Submit your abstract Today

Watsapp